Back to all studiesActive Not RecruitingNCT05370911
Effects of Repeated Psilocybin Dosing in OCD
Official study titleEffects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study
Medication studyAges 18–65United States
The study in practiceUnderstand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarifyThis summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Study clarityThings to check before joining
Study start dateStarted: July 20, 2023
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 28
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05370911
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05370911. We help you review the study, but cannot decide medical eligibility.
A listed location does not confirm current availability.
FAQQuestions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including Psilocybin.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
Explore other studiesWant to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me